Sage Therapeutics, Inc.
SAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.36 | -0.43 | 0.03 |
| FCF Yield | -80.98% | -41.73% | -20.38% | -15.17% |
| EV / EBITDA | -0.64 | -2.26 | -3.87 | -4.86 |
| Quality | ||||
| ROIC | -90.66% | -72.06% | -40.60% | -25.86% |
| Gross Margin | 77.10% | 97.50% | 89.42% | 91.23% |
| Cash Conversion Ratio | 0.67 | 1.00 | 0.86 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 75.07% | 139.31% | -80.96% | -2.80% |
| Free Cash Flow Growth | 50.62% | -17.39% | -21.77% | -157.02% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 0.12 | 0.28 | 0.60 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.01 | -0.03 |
| Cash Conversion Cycle | -409.97 | -1,393.91 | -36,810.27 | -18,041.19 |